Abstract
Background Disease-related gait dysfunction causes extensive disability for persons with Parkinson's disease (PD), with no effective therapies currently available. The potassium channel blocker dalfampridine has been used in multiple neurological conditions and improves walking in persons with multiple sclerosis. Objectives We aimed to evaluate the effect of dalfampridine extended release (D-ER) 10 mg tablets twice daily on different domains of walking in participants with PD. Methods Twenty-two participants with PD and gait dysfunction were randomized to receive D-ER 10 mg twice daily or placebo for 4 weeks in a crossover design with a 2-week washout period. The primary outcomes were change in the gait velocity and stride length. Results At 4 weeks, gait velocity was not significantly different between D-ER (0.89 m/s ± 0.33) and placebo (0.93 m/s ± 0.27) conditions. The stride length was also similar between conditions: 0.96 m ± 0.38 for D-ER versus 1.06 m ± 0.33 for placebo. D-ER was generally well tolerated with the most frequent side effects being dizziness, nausea and balance problems. Conclusions D-ER is well tolerated in PD patients, however it did not show significant benefit for gait impairment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 7-11 |
| Number of pages | 5 |
| Journal | Journal of the Neurological Sciences |
| Volume | 379 |
| DOIs | |
| State | Published - Aug 15 2017 |
Fingerprint
Keywords
- Dalfampridine
- Freezing of gait
- Gait dysfunction
- Parkinson's disease
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Cite this
Dalfampridine in Parkinson's disease related gait dysfunction : A randomized double blind trial. / Luca, Corneliu C; Nadayil, Gloria; Dong, Chuanhui; Nahab, Fatta B.; Field-Fote, Edelle; Singer, Carlos.
In: Journal of the Neurological Sciences, Vol. 379, 15.08.2017, p. 7-11.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dalfampridine in Parkinson's disease related gait dysfunction
T2 - A randomized double blind trial
AU - Luca, Corneliu C
AU - Nadayil, Gloria
AU - Dong, Chuanhui
AU - Nahab, Fatta B.
AU - Field-Fote, Edelle
AU - Singer, Carlos
PY - 2017/8/15
Y1 - 2017/8/15
N2 - Background Disease-related gait dysfunction causes extensive disability for persons with Parkinson's disease (PD), with no effective therapies currently available. The potassium channel blocker dalfampridine has been used in multiple neurological conditions and improves walking in persons with multiple sclerosis. Objectives We aimed to evaluate the effect of dalfampridine extended release (D-ER) 10 mg tablets twice daily on different domains of walking in participants with PD. Methods Twenty-two participants with PD and gait dysfunction were randomized to receive D-ER 10 mg twice daily or placebo for 4 weeks in a crossover design with a 2-week washout period. The primary outcomes were change in the gait velocity and stride length. Results At 4 weeks, gait velocity was not significantly different between D-ER (0.89 m/s ± 0.33) and placebo (0.93 m/s ± 0.27) conditions. The stride length was also similar between conditions: 0.96 m ± 0.38 for D-ER versus 1.06 m ± 0.33 for placebo. D-ER was generally well tolerated with the most frequent side effects being dizziness, nausea and balance problems. Conclusions D-ER is well tolerated in PD patients, however it did not show significant benefit for gait impairment.
AB - Background Disease-related gait dysfunction causes extensive disability for persons with Parkinson's disease (PD), with no effective therapies currently available. The potassium channel blocker dalfampridine has been used in multiple neurological conditions and improves walking in persons with multiple sclerosis. Objectives We aimed to evaluate the effect of dalfampridine extended release (D-ER) 10 mg tablets twice daily on different domains of walking in participants with PD. Methods Twenty-two participants with PD and gait dysfunction were randomized to receive D-ER 10 mg twice daily or placebo for 4 weeks in a crossover design with a 2-week washout period. The primary outcomes were change in the gait velocity and stride length. Results At 4 weeks, gait velocity was not significantly different between D-ER (0.89 m/s ± 0.33) and placebo (0.93 m/s ± 0.27) conditions. The stride length was also similar between conditions: 0.96 m ± 0.38 for D-ER versus 1.06 m ± 0.33 for placebo. D-ER was generally well tolerated with the most frequent side effects being dizziness, nausea and balance problems. Conclusions D-ER is well tolerated in PD patients, however it did not show significant benefit for gait impairment.
KW - Dalfampridine
KW - Freezing of gait
KW - Gait dysfunction
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=85019404751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019404751&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2017.05.011
DO - 10.1016/j.jns.2017.05.011
M3 - Article
C2 - 28716283
AN - SCOPUS:85019404751
VL - 379
SP - 7
EP - 11
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
SN - 0022-510X
ER -